Notice: This company has been marked as potentially delisted and may not be actively trading. XTL Biopharmaceuticals (XTLB) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsEarningsHeadlinesShort InterestTrends XTLB vs. TPST, CLNN, QTTB, VYNE, BIVI, LTRN, SCNX, GRCE, RLYB, and VIRIShould you be buying XTL Biopharmaceuticals stock or one of its competitors? The main competitors of XTL Biopharmaceuticals include Tempest Therapeutics (TPST), Clene (CLNN), Q32 Bio (QTTB), VYNE Therapeutics (VYNE), BioVie (BIVI), Lantern Pharma (LTRN), Scienture (SCNX), Grace Therapeutics (GRCE), Rallybio (RLYB), and Virios Therapeutics (VIRI). These companies are all part of the "pharmaceutical preparations" industry. XTL Biopharmaceuticals vs. Tempest Therapeutics Clene Q32 Bio VYNE Therapeutics BioVie Lantern Pharma Scienture Grace Therapeutics Rallybio Virios Therapeutics Tempest Therapeutics (NASDAQ:TPST) and XTL Biopharmaceuticals (NASDAQ:XTLB) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, risk, earnings, analyst recommendations, institutional ownership, profitability, valuation, community ranking and dividends. Which has more risk and volatility, TPST or XTLB? Tempest Therapeutics has a beta of -1.69, suggesting that its share price is 269% less volatile than the S&P 500. Comparatively, XTL Biopharmaceuticals has a beta of 1.14, suggesting that its share price is 14% more volatile than the S&P 500. Do institutionals & insiders have more ownership in TPST or XTLB? 22.5% of Tempest Therapeutics shares are owned by institutional investors. Comparatively, 4.4% of XTL Biopharmaceuticals shares are owned by institutional investors. 4.7% of Tempest Therapeutics shares are owned by company insiders. Comparatively, 29.0% of XTL Biopharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Does the MarketBeat Community believe in TPST or XTLB? Tempest Therapeutics received 21 more outperform votes than XTL Biopharmaceuticals when rated by MarketBeat users. However, 71.82% of users gave XTL Biopharmaceuticals an outperform vote while only 65.79% of users gave Tempest Therapeutics an outperform vote. CompanyUnderperformOutperformTempest TherapeuticsOutperform Votes10065.79% Underperform Votes5234.21% XTL BiopharmaceuticalsOutperform Votes7971.82% Underperform Votes3128.18% Does the media refer more to TPST or XTLB? In the previous week, Tempest Therapeutics had 1 more articles in the media than XTL Biopharmaceuticals. MarketBeat recorded 3 mentions for Tempest Therapeutics and 2 mentions for XTL Biopharmaceuticals. Tempest Therapeutics' average media sentiment score of 1.44 beat XTL Biopharmaceuticals' score of 0.00 indicating that Tempest Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Tempest Therapeutics Positive XTL Biopharmaceuticals Neutral Do analysts recommend TPST or XTLB? Tempest Therapeutics presently has a consensus target price of $20.00, suggesting a potential upside of 2,016.40%. Given Tempest Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Tempest Therapeutics is more favorable than XTL Biopharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tempest Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00XTL Biopharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Is TPST or XTLB more profitable? XTL Biopharmaceuticals' return on equity of 0.00% beat Tempest Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Tempest TherapeuticsN/A -187.44% -82.61% XTL Biopharmaceuticals N/A N/A N/A Which has stronger earnings & valuation, TPST or XTLB? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTempest TherapeuticsN/AN/A-$29.49M-$1.53-0.62XTL BiopharmaceuticalsN/AN/A-$1.78MN/AN/A SummaryTempest Therapeutics beats XTL Biopharmaceuticals on 7 of the 13 factors compared between the two stocks. Get XTL Biopharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for XTLB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart XTLB vs. The Competition Export to ExcelMetricXTL BiopharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$10.08M$6.90B$5.61B$9.12BDividend YieldN/A2.95%5.36%3.98%P/E RatioN/A10.0389.5417.51Price / SalesN/A348.831,227.0083.27Price / CashN/A65.0944.3037.67Price / Book3.985.295.124.72Net Income-$1.78M$154.95M$117.78M$224.62M XTL Biopharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)XTLBXTL Biopharmaceuticals0.2924 of 5 stars$1.63-12.4%N/A+98.3%$10.08MN/A0.00N/AShort Interest ↑Gap DownTPSTTempest Therapeutics2.4141 of 5 stars$0.93+3.4%$20.00+2,060.5%-74.5%$40.40MN/A-0.6120Short Interest ↓Positive NewsCLNNClene3.0775 of 5 stars$4.79-2.0%$55.25+1,053.4%-54.3%$40.04M$650,000.00-0.91100News CoveragePositive NewsQTTBQ32 Bio3.5451 of 5 stars$3.28+4.5%$29.86+810.3%N/A$39.95M$1.16M-0.2339Short Interest ↑VYNEVYNE Therapeutics3.4411 of 5 stars$2.70+4.7%$6.88+154.6%+31.8%$39.83M$420,000.00-3.1430Short Interest ↑Positive NewsBIVIBioVie1.9384 of 5 stars$2.24+0.4%$3.00+33.9%+57.5%$39.81MN/A-0.1910Short Interest ↓LTRNLantern Pharma0.9774 of 5 stars$3.69+2.5%N/A+17.6%$39.78MN/A-2.0720Gap UpSCNXScientureN/A$4.36-4.6%N/AN/A$38.15M$8.27M0.00N/APositive NewsGap DownGRCEGrace TherapeuticsN/A$3.66+8.9%N/AN/A$37.11MN/A-3.62N/ANews CoverageRLYBRallybio3.4466 of 5 stars$0.88-1.7%$9.75+1,014.0%-36.9%$36.31MN/A-0.5540VIRIVirios Therapeutics0.3784 of 5 stars$1.87-3.1%$3.00+60.4%+2,829.3%$36.01MN/A-6.935 Related Companies and Tools Related Companies Tempest Therapeutics Competitors Clene Competitors Q32 Bio Competitors VYNE Therapeutics Competitors BioVie Competitors Lantern Pharma Competitors Scienture Competitors Grace Therapeutics Competitors Rallybio Competitors Virios Therapeutics Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:XTLB) was last updated on 1/31/2025 by MarketBeat.com Staff From Our Partners Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored#1 Crypto of 2025Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode in 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe crypto bull market is here, and the stakes couldn’t be higher. The next 3-6 months? They’re the most ex...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding XTL Biopharmaceuticals Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share XTL Biopharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free XTLB Stock Alerts